Agilgen
Agilgen
  • Home
  • AI Drug Design
  • AI Solid Form Engineering

AI-Driven Solid Form Engineering

Stability Optimization & Manufacturability Enhancement for Clinical-Stage Assets

  • Unexpected polymorph behavior is not just a theoretical risk — it is a manufacturability variable.
  • In clinical-stage small molecules, narrow thermodynamic separation between structurally distinct forms can reduce crystallization robustness and increase process sensitivity during scale-up or tech transfer.
  • We help teams quantify stability margin and engineer more controllable solid-form strategies before critical CMC milestones.

Why This Matters in Development

 Polymorph confirmation at lab scale does not guarantee process robustness. When alternative forms exist within a narrow stability window (<1 kcal/mol), competitive behavior may emerge under:

  • • Solvent variation
    • Scale-dependent crystallization kinetics
    • Slurry aging
    • Tech transfer
    • Process stress

This can result in:

  • • Unexpected form conversion
    • Batch variability
    • Additional crystallization optimization
    • Extended analytical investigation
    • CMC clarification cycles

Solid-form robustness is a development variable — not just a discovery observation..

What We Deliver

Our program goes beyond risk identification. We provide structured engineering insight:

  • • Crystal structure prediction landscape mapping
    • Quantitative thermodynamic stability margin analysis
    • Energy–density competition mapping
    • Packing motif differentiation
    • Competitive polymorph window definition
    • Engineering guidance to enhance robustness
    • Executive-level summary for decision support

Turnaround: 2–3 weeks
Designed for milestone-aligned decision-making.

When Teams Engage Us

  • Preparing for Phase I or Phase II scale-up
  • Strengthening CMC package prior to BD discussions
  • Evaluating robustness before tech transfer 
  • Investigating unexpected solid-form behavior 
  • Exploring alternative forms to enhance manufacturability 

Discuss Your Program

If your team is advancing a small-molecule asset toward clinical expansion or manufacturing scale-up, we would be glad to review your development context. Contact: wayne.wang@agilgen.com 

www.agilgen.com

Hours

Today

Closed

If your team is advancing a small-molecule asset toward clinical expansion or manufacturing scale-up, we would be glad to review your development context. Schedule a 20-minute discussion. Contact: wayne.wang@agilgen.com

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel

Copyright © 2026 agilgen.com - All Rights Reserved.


Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept